Organon & Co reported $8.9B in Debt for its fiscal quarter ending in June of 2025.




Debt Change Date
Adcock Ingram Holdings ZAR 969.4M 688.86M Dec/2024
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Celltrion KRW 2.22T 24.87B Mar/2025
Cspc Pharmaceutical CNY 507.33M 118.46M Dec/2024
Dianthus Therapeutics USD 1.33M 161K Jun/2025
Divis Laboratories Ltd 40M 40M Mar/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Glaxosmithkline GBP 17.35B 368M Jun/2025
Kangmei Pharma CNY 221.82M 958.68M Mar/2025
Knight Therapeutics CAD 58.22M 109K Sep/2024
Laboratorios Farma EUR 129.3M 14.89M Jun/2025
Malin Corporation EUR 0 0 Dec/2024
Medical Developments International AUD 2.14M 144K Dec/2024
Merck USD 34.84B 2.27B Mar/2025
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Novartis USD 32.64B 1.38B Jun/2025
Organigram Holdings CAD 9.15M 35.6M Jun/2025
Organon & Co USD 8.9B 60M Jun/2025
Pharma Mar EUR 51.4M 405K Jun/2025
Qiagen NV USD 1.44B 35.7M Jun/2025
Sartorius EUR 4.66B 25.7M Jun/2025
Sino Biopharmaceutical CNY 9.71B 33.98M Dec/2024
Tilray USD 351.72M 15.26M Nov/2024